|
3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
|
DB08093 |
|
|
(4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE
|
DB08094 |
|
|
3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
|
DB08095 |
|
|
8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
|
DB08096 |
|
|
2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
|
DB08097 |
|
|
{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid
|
DB08098 |
[This compound belongs to the nitrofurans. These are compounds containing a furan ring which bears a nitro group. It targets the protein aldose reductase.] |
|
6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine
|
DB08099 |
[6-ethyl-5-[(2s)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine is a solid. This compound belongs to the phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group. This substance targets the protein renin.] |
|
Bombesin
|
DB11724 |
[Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers).] |
|
Dutogliptin
|
DB11723 |
[Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.] |
|
Iocetamic acid
|
DB09403 |
[Iocetamic acid is a diagnostic aid (radiopaque medium)] |
|
Mitoglitazone
|
DB11721 |
[Mitoglitazone has been used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.] |
|
Endostar
|
DB11727 |
[Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.] |
|
Magnesium chloride
|
DB09407 |
[Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water.] |
|
Encenicline
|
DB11726 |
[Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.] |
|
Latrepirdine
|
DB11725 |
[Latrepirdine has been investigated for the treatment of Alzheimer's Disease and Huntington's Disease.] |
|
Magnesium acetate tetrahydrate
|
DB09409 |
[Magnesium acetate tetrahydrate is a hydrated form of anhydrous magnesium acetate salt with the chemical formula of Mg(CH3COO)2 • 4H2O. As a salt form of magnesium, magnesium acetate is one of the bioavailable forms of magnesium and forms a very water soluble compound. Magnesium is an essential element and second most abundant cation in the body that plays a key role in maintaining normal cellular function such as production of ATP and efficient enzyme activity. Magnesium acetate tetrahydrate can be used as an electrolyte supplementation or a reagent in molecular biology experiments.] |
|
Angiotensin 1-7
|
DB11720 |
[TXA127 has been investigated for the treatment of Miscellaneous Peripheral Blood Cell Abnormalities.] |
|
UK-390957
|
DB11719 |
[UK-390,957 has been used in trials studying the treatment of Ejaculation.] |
|
Encorafenib
|
DB11718 |
[Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations [FDA label]. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung [L3344].
On June 27, 2018, the Food and Drug Administration approved encorafenib and [Binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [FDA label].] |
|
Selenomethionine Se-75
|
DB09400 |
|
